From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2017 call → NOWe need answer only YES or NO. Need analyze transcript. Question asks whether management describes recently crossed into approved/specified/list qualified etc inside buyers' purchasing systems, so future business arrives without discrete selling event, and status new enough most volume ahead. We need look at transcript. Company Atmos Energy, natural gas utility. They discuss rate cases, regulatory filings, capital investments. They mention "rate outcomes" and "rate relief" primary driver. They have rate mechanisms, GRIP statute, annual rate review mechanisms. They are regulated utility. The question is about being placed into buyer's purchasing/reimbursement/formulary etc. For utility, rate base and regulatory approvals? They have "rate filings" that provide increases. But is that "access status" like being approved supplier? Hmm. The phenomenon: company has moved from candidate toward default inside routine pathway through which purchases get made. For utility, perhaps regulatory rate case approval allows rates to be collected automatically from customers without selling each order. But is that "recently crossed"? They mention "we've begun our sixth consecutive year of executing our strategy" and "rate outcomes have provided annual operating increases of about $20 million and filed cases pending." They have ongoing rate mechanisms. But the question asks if management describes that company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing... systems — so that meaningful portion future business can arrive WITHOUT discrete selling event — AND management conveys this access status is new enough that most volume still ahead. In transcript, management talks about regulatory rate cases, GRIP statute, annual rate mechanisms. They are already in these mechanisms for years. They mention "we've begun our sixth consecutive year of executing our strategy" and "rate outcomes" are primary driver. They have "rate filings" that provide increases. But is that "recently crossed"? No, it's ongoing. They also mention "we're now the largest pure play natural gas only distributor" after divesting non-regulated. But that's not about access.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.